Ride along on a bike commute from Carmel to downtown Indy
IBJ reporter Gabrielle Poshadlo follows Don Jarrels on his daily jaunt downtown. Bonus video: A look inside Eli Lilly and Co.'s bike-to-work program.
Home » Search
Search Results
4,410 results for '\"eli lilly\"'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
Company news
In a deal with Eli Lilly and Co., New York-based Advion BioSciences Inc. will open a 22,000-square-foot drug discovery bioanalytical laboratory in May at the Purdue Research Park in Indianapolis. Lilly, the Indianapolis-based drugmaker, will move its own drug-discovery bioanalytical operations to Advion as part of the partnership and retain some oversight. The lab initially will employ 49 people and could ramp up to 66 workers by 2015. Lilly expects 26 employees to lose their jobs but will be able to apply for limited positions within Lilly or at Advion’s Indianapolis lab. Advion will focus on earlier-stage, drug-discovery bioanalytical services, which evaluate how a potential new medicine is absorbed and metabolized in experimental models. Many of the activities performed at the lab are required for the preparation of a molecule’s entry into human testing. Indiana Economic Development Corp. offered Advion up to $650,000 in performance-based tax credits and up to $30,000 in training grants based on the company's job-creation plans. Develop Indy will provide additional training funding and support property-tax abatement from the city of Indianapolis.
Hall, Render, Killian, Heath & Lyman added 24 attorneys last year as the health reform law generated a wave of legal work for its clients. Of those new hires, four were added to Hall Render’s headquarters office in Indianapolis, with the rest spread among the firm’s offices in Milwaukee, Louisville and Troy, Mich. Hall Render already had the second-most health care attorneys of any firm in the nation, according to a ranking published in June 2010 by Modern Healthcare magazine. Hall Render now has more than 150 attorneys who are members of the American Health Lawyers Association. The firm with the most health attorneys last year was Atlanta-based King & Spalding, with 229.
UPDATE: Bioanalytical researcher opening lab in Indianapolis
Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of a partnership.
City-County Council OKs North of South project funding
The $155 million complex, to be built primarily on Eli Lilly and Co.-owned parking lots at Delaware and South streets, is to include a boutique hotel, a YMCA, apartments and retail and office space.
North of South development to start this summer
Now that financing for Buckingham Cos.’ massive project has the city’s blessing, the local developer is turning its full attention to construction of the 14-acre, mixed-use complex.
UPDATE: Lilly settles pollution suit for $337,500
The agreement with the U.S. government calls for the pharmaceutical company to pay a $337,500 penalty for allegedly emitting a high level of hazardous pollutants from its manufacturing plant on South Harding Street.
UPDATE: Lilly settles pollution suit for $337,500
A complaint filed Wednesday by the U.S. government says Lilly’s plant on South Harding Street is emitting high levels of acetonitrile and methanol, considered hazardous air pollutants by the EPA.
Eli Lilly neuroscience chief resigns
David Bredt, vice president of neuroscience research, has resigned “to pursue other opportunities,” according to Lilly spokeswoman Judy Kay Moore. Bredt had overseen Lilly’s development of various drugs, including molecules in late-stage human testing to treat Alzheimer’s and depression.
Company news
It’s no secret Wall Street analysts take a dim view of Eli Lilly and Co.’s future profit potential. Only two out of 22 analysts recommend buying the Indianapolis-based company’s stock. And here’s why: Lilly ranks last among nine pharmaceutical companies in pipeline sales potential by the year 2015, according to an analysis by Dr. Tim Anderson, a pharmaceutical analyst at Bernstein Research. Anderson adds up the five-year sales forecasts for all drugs under development by the nine drugmakers. Pharmaceutical journalist Jim Edwards noted that such predictions are notoriously unreliable, but it’s the best investors have to go on for predicting the pharma future. At the top of Anderson’s ranking is Switzerland-based Novartis AG, estimated to generate $4.5 billion in sales from pipeline drugs by 2015. Lilly brings up the rear with $1 billion in projected sales. Smack in the middle of the list is New York-based Bristol-Myers Squibb Co., which is roughly equal in size to Lilly and is projected to pull in $3.2 billion from pipeline drugs.
CNO Financial Group Inc. boosted its operating profits 62 percent in the fourth quarter, besting analysts’ estimates by 2 cents per share. The Carmel-based life and health insurer on Tuesday said it earned $168.2 million in the final three months of last year, a big jump from the $18.2 million profit it posted in the same quarter the prior year. Most of the increase in the most recent quarter came from investment gains. Excluding those, as well as special accounting and debt charges, CNO had a quarterly operating profit of $51.7 million, or 18 cents per common share. On that same basis, Wall Street analysts were expecting the company to earn 16 cents per share, according to a survey by Thomson Reuters. A year ago, CNO’s operating profit was $32 million, or 15 cents per share. Revenue for the quarter rose nearly 2 percent to $1.08 billion. The main improvement came on policies that CNO still holds but is no longer actively selling. That division, called “Other CNO Business,” recorded a fourth-quarter profit of $6 million, compared with a nearly $30 million loss in the same quarter last year. That helped mask a drop in profit at CNO’s main Bankers Life unit, based in Chicago. It earned $71.4 million in the quarter, a fall of 16 percent.
People
Community Health Network appointed registered nurse Cindy Adams its chief nursing officer, overseeing 3,000 nurses. On Feb. 26, Adams will replace Jan Bingle, who is retiring after 27 years at Community. Adams holds degrees from Ball State and Indiana universities. She resides in Shelbyville.
Dr. Marc Overhage is leaving Indianapolis-based Indiana Health Information Exchange Inc. to become chief medical informatics officer of Siemens, a German company with its U.S. health services business unit based in Pennsylvania. Until earlier this year, Overhage was CEO of the exchange, but stepped down and was replaced by local software entrepreneur Harold Apple.
Dr. Isaac J. Myers II will become president of St. Francis Medical Group on Feb. 28. Myers was previously vice president of clinical and business integration at Wishard Health Services. From 1998 to 2006, Myers was vice president of medical affairs for Advantage Health Solutions, a health insurer in Indianapolis. A New York City native, Myers earned his medical degree from Wayne State School of Medicine and performed his residency in family medicine at Indiana University School of Medicine.
Dr. James L. Gahimer has established a practice with the newly created Center Grove Internal Medicine in Greenwood, which is part of the St. Francis Medical Group. Gahimer previously worked as a drug safety consultant with T.L. Care Corp in Beech Grove, and before that was a medical adviser in global product safety at Eli Lilly and Co.
Lilly looks to double pipeline size again
Indianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to 60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this alternative pipeline.
Immigration bill’s author won’t vote on own bill
Republican Sen. Mike Delph of Carmel, the author of a contentious Arizona-style bill to crack down on illegal immigration in Indiana, won't be present if the state Senate votes on the measure Tuesday.
Emerging markets give Lilly hope in patent crunch
In a kind of alternate drug universe, sales of Eli Lilly and Co.’s ghosts of blockbusters past are soaring in China—prompting the drugmaker to pour money into emerging markets in an attempt to prop up revenue.
Lilly’s master plan for downtown (real estate)
As Eli Lilly and Co. outsources work and sheds unnecessary properties, it is making moves with surplus real estate that could establish the strongest physical connection between Lilly and downtown since the company was founded at Pearl and Meridian streets 135 years ago.
UPDATE: House votes to kill pricey jet fighter engine
The decision on military budget cuts could have a big impact on the Indianapolis operations of Rolls-Royce Corp., the city’s second-largest manufacturer behind Eli Lilly and Co.
Company news
A proposal that would make it easier for Eli Lilly and Co. to be purchased in an unwanted takeover will be voted on again by shareholders at the company’s annual meeting. The effort to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly’s board is on the agenda of the April 18 meeting. The proposal failed last year after receiving approval from 74 percent of shareholders owning Lilly stock. To pass, it needed the support of investors holding 80 percent of all of Lilly’s outstanding shares. The supermajority vote requirement, which has been in place for more than 25 years, applies not only to outright takeover bids, but also to measures used to achieve them, such as removing directors before their terms end or expanding the size of the board. If the proposal passes, it would require a bare majority of votes to approve such actions in the future.
A researcher at the Indiana University School of Medicine and the Regenstrief Institute Inc. has received a $420,000 grant to use computer technology to manage patients after they leave hospitals. Dr. Martin Chieng Were’s research focused on patients who are discharged from a hospital even when results from their medical tests are still pending. Poor communication and management of such patients leads to serious medical errors in the patients’ follow-up care, Were has shown. The grant is from the Robert Wood Johnson Foundation.
Arcadia Resources Inc. continued to shed money in its most recent quarter but took a smaller loss than it did in the same period of 2009. Indianapolis-based Arcadia lost $2.3 million, or 1 cent per share, on revenue of $26.2 million in its third fiscal quarter, which ended Dec. 31. That compares to a loss of $3.2 million, or 2 cents per share, on revenue of $25.7 million for the same quarter in 2009. In its pharmacy segment, Arcadia reported revenue of $5 million in the latest quarter, marking a 22.6-percent increase for its DailyMed medication-management system over the same period in 2009. Arcadia’s DailyMed service packages doses of prescriptions into individual packets, to make it easier for patients on numerous medications to stick to their regimens. DailyMed currently is offered in WellPoint-affiliated health plans in California, Kansas, South Carolina and Virginia.
Lilly names new head of cancer drug business
Eli Lilly and Co. on Friday named company insider Sue Mahony as president of its cancer drug business.
Lilly takeover provision to be voted on again
The effort to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly’s board is on the agenda of the company’s April 18 annual meeting.
City agency signs off on North of South site plans
Regional Center Hearing Examiner gives blessing to the $155 million development’s master plan. Site plans will go before the Metropolitan Development Commission on March 2.